Gastric cancer (GC) is one of the most common malignant tumors, and most GC patients in China are diagnosed as progressive GC at their first visit and late stage patients fail to have surgical treatment. The effects of conventional treatments, including chemotherapy, radiotherapy and targeted therapy, are limited and may induce poor prognosis. As a new treatment in hematological malignancy, chimeric antigen receptor (CAR)-T cell (CAR-T) immunotherapy is indicated as a promising treatment for advanced GC, which paves a new way for the GC immunotherapy. However, there are still some obstacles to overcome, such as the heterogeneity of GC, immunosuppression of tumor microenvironment, tumor target antigen escape and off-target toxicity. In this review, the CAR structure, therapeutic principle of CAR-T, and the main targets and treatment status of CAR-T immunotherapy for advanced GC are reviewed; the challenges faced by CAR-T immunotherapy in GC are discussed, so as to provide new ideas for the clinical immunotherapy of advanced GC.